Drugs that contain Flotufolastat F-18 Gallium
1. Posluma patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11413360 | BLUE EARTH | Dual mode radiotracer and—therapeutics |
Nov, 2038
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 25, 2028 |
NCE-1 date: 26 May, 2027
Market Authorisation Date: 25 May, 2023
Treatment: Positron emission tomography (pet) of prostate-specific membrane antigen (psma) positive lesions in men with prostate cancer with suspected recurrence based on elevated serum prostate-specific antigen...
Dosage: SOLUTION;INTRAVENOUS
More Information on Dosage
POSLUMA family patents
